Small cell lung cancer · line 2 · Topotecan (SCLC relapsed/refractory)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-TOPOTECAN-SCLC-RR |
| ID | IND-SCLC-RR-TOPOTECAN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-SCLC |
| Sources | SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
Standard-track 2L for R/R SCLC. Topotecan is NCCN Category 1 and remains the de-facto Ukraine standard (registered, NSZU-reimbursable) vs lurbinectedin (aggressive track, NCCN Cat 2A, not registered UA). CTFI stratification is key: ≥180 days → consider platinum rechallenge first; 30-180 days → lurbinectedin preferred (aggressive) or topotecan (standard); <30 days → topotecan. Oral topotecan equivalent by OS but unavailable in Ukraine.
Used By
Algorithms
ALGO-SCLC-2L- ALGO-SCLC-2L
Indication
IND-SCLC-PLATINUM-RECHALLENGE- IND-SCLC-PLATINUM-RECHALLENGE